daawaynta kansarka sambabada unug yar oo aan yarayn

Kansarka sambabada unugyada aan yarayn (NSCLC) waa nooca caadiga ah ee kansarka sanbabada. Ikhtiyaarada daawaynta ee NSCLC waa kala duwan yihiin waxayna ku xidhan yihiin dhawr arrimood, oo ay ku jiraan heerka kansarka, caafimaadka guud ee bukaanka, iyo isbeddellada hidde-sidaha gaarka ah ee ku jira burada. Hagahan waxa uu bixiyaa dulmar guud oo ku saabsan hababka daawaynta ugu muhiimsan ee NSCLC, laga bilaabo qaliinka iyo daaweynta shucaaca ilaa daawaynta la beegsaday iyo immunotherapy, xoojinta bukaanka iyo daryeelayaasha aqoonta si ay u qaataan go'aamo xog ogaal ah.Kansarka sambabada unugyada aan yarayn (NSCLC) waa koox ka mid ah kansarka sanbabada oo u dhaqma si la mid ah. Noocyada ugu muhiimsan ee NSCLC waxaa ka mid ah adenocarcinoma, kansarka unugyada squamous, iyo kansarka unugyada waaweyn. Ogaanshaha saxda ah, oo ay ku jiraan diyaarinta iyo baaritaanka molecular, ayaa muhiim u ah go'aaminta istaraatiijiyada daaweynta ugu waxtarka badan. Machadka Cilmi-baarista Kansarka Shandong Baofa wuxuu u heellan yahay cilmi-baarista kansarka iyo horumarinta hababka cusub ee daaweynta, wax badan ka baro https://baofahospital.com.Staging of NSCLCNSCLC waxaa loo habeeyey iyadoo la isticmaalayo nidaamka TNM (Tumor, Node, Metastasis). Marxaladu waxay sharraxaysaa cabbirka iyo meesha ay ku taal burada asaasiga ah (T), haddii kansarku uu ku faafay qanjidhada u dhow (N), iyo haddii kansarku uu basbeelay meelo fog (M). Marxaladaha waxay u dhexeeyaan I (marxaladda hore) ilaa IV (marxaladda sare). Kuwan biomarkers waxay kaa caawin karaan go'aaminta haddii bukaanku yahay musharaxa daaweynta la beegsaday. Isbeddellada caadiga ah waxaa ka mid ah EGFR, ALK, ROS1, BRAF, iyo kuwa kale. Natiijooyinka baaritaanka molecular waxay si weyn u saameeyaan go'aamada daaweynta.Standard Daawaynta NSCLCQalliinka Qaliinka badanaa waa daawaynta safka hore ee NSCLC-da (marxaladihii I iyo II). Hadafka waa in meesha laga saaro burada iyo qanjidhada u dhow. Noocyada qaliinka waxaa ka mid ah: Dib-u-habaynta Wedge: Ka saarida gabal yar oo sambabada u eg. Segmentectomy: Ka saarida qayb ka weyn sambabada marka loo eego goynta goynta. Lobectomy: Ka saarida dhammaan lafaha sambabada. Tani waa habka ugu badan ee qaliinka ee NSCLC. Pneumonectomy: Ka saarida sambabada oo dhan. Tani waa mid aad u yar oo loo qoondeeyay burooyin aad u ballaaran. Daaweynta shucaaca waxay isticmaashaa fallaadhaha tamarta sare si ay u disho unugyada kansarka. Waxa loo isticmaali karaa daawaynta aasaasiga ah, qalitaanka ka dib si loo dilo unugyada kansarka ee hadhay, ama in la yareeyo calaamadaha (shucaaca palliative). Noocyada kala duwan ee daaweynta shucaaca waxaa ka mid ah: Daaweynta Shucaaca Beam ee Dibadda (EBRT): Shucaaca waxa laga keenaa mishiin ka baxsan jidhka. Daaweynta Shucaaca Jirka ee Stereotactic (SBRT): Wuxuu keenaa qiyaas sare oo shucaac ah meel yar oo si sax ah loo beegsaday. Badanaa waxaa loo isticmaalaa marxaladda hore ee NSCLC marka qaliinku aanu ahayn ikhtiyaar. Brachytherapy (Daawaynta Shucaaca Gudaha): Waxyaabo shucaac ah ayaa si toos ah loogu dhejiyaa gudaha burada ama meel u dhow. Daaweynta Kiimikada Kiimikada waxay isticmaashaa daawooyinka si ay u disho unugyada kansarka ee jirka oo dhan. Badanaa waxaa loo adeegsadaa qalliin ama daawaynta shucaaca, ama sida daawaynta aasaasiga ah ee horumarsan NSCLC. Daawooyinka kemotherabi ee caadiga ah ee NSCLC waxaa ka mid ah cisplatin, carboplatin, paclitaxel, docetaxel, pemetrexed, iyo gemcitabine. Daawaynta NSCLCDaawaynta la beegsaday waa dawooyin bartilmaameedsada unugyo gaar ah oo ku lug leh koritaanka unugyada kansarka iyo badbaadada. Daawayntani waxay wax ku ool tahay kaliya haddii buradu leedahay isbeddel hidde-side gaar ah ama cillad borotiinka ah. NSCLC oo leh isbeddellada EGFR. Daawooyinkani waxay xannibaan borotiinka EGFR, kaas oo caawiya koritaanka unugyada kansarka. Tusaalooyinka waxaa ka mid ah: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso) ALK InhibitorsALK (anaplastic lymphoma kinase) horjoogayaasha ayaa loo isticmaalaa in lagu daweeyo NSCLC oo leh dib u habeynta hidda-wadaha ALK. Daawooyinkani waxay xannibaan borotiinka ALK, kaas oo caawiya koritaanka unugyada kansarka. Tusaalooyinka waxaa ka mid ah: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena) ROS1 InhibitorsROS1 inhibitors ayaa loo isticmaalaa in lagu daweeyo. NSCLC oo leh dib u habeynta hidda-wadaha ROS1. Daawooyinkani waxay xannibaan borotiinka ROS1, kaas oo caawiya koritaanka unugyada kansarka. Tusaalooyinka waxaa ka mid ah: Crizotinib (Xalkori) Entrectinib (Rozlytrek) BRAF Inhibitors BRAF ayaa loo isticmaalaa in lagu daaweeyo NSCLC oo leh isbeddellada BRAF V600E. Daawooyinkani waxay xannibaan borotiinka BRAF. Tusaalooyinka waxaa ka mid ah: Dabrafenib (Tafinlar) Trametinib (Mekinist) (oo lagu daray Dabrafenib)Daawaynta kale ee la beegsaday Tusaalooyinka waxaa ka mid ah RET inhibitors (oo loogu talagalay fusions RET) iyo MET inhibitors (oo loogu talagalay MET exon 14 beddelka boodboodka).Immunotherapy Daawaynta NSCLCDaawooyinka Immunotherapy waxay ka caawiyaan habka difaaca jidhku inuu la dagaallamo kansarka. Waxay ku shaqeeyaan iyagoo xannibaya borotiinnada ka hortagaya habka difaaca jirka inuu weeraro unugyada kansarka. Kuwan ayaa inta badan lagu isticmaalaa gudaha NSCLC daaweynta.PD-1/PD-L1 InhibitorsPD-1 (programmed protein death protein 1) iyo PD-L1 (barnaamijka dhimashada-ligand 1) inhibitors-ku waxay xannibaan waddada PD-1 / PD-L1, taas oo ka caawisa unugyada kansarka inay ka baxsadaan nidaamka difaaca. Tusaalooyinka waxaa ka mid ah: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo) CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-ku xiran borotiinka 4) ka hortagga unugyada kansarka, sidoo kale waxay ka hortagtaa unugyada kansarka. Tusaale ahaan Ipilimumab (Yervoy), oo inta badan loo isticmaalo marka lagu daro PD-1 inhibitors. daawaynta NSCLC ku lug lahaansho isku-dar ah daaweyno kala duwan. Tusaale ahaan, qalliinka waxaa ku xigi kara kiimoterabi ama daaweynta shucaaca. Daawaynta la beegsaday ama immunotherapy ayaa lagu dari karaa daawaynta kiimoterabi. Isku darka gaarka ah wuxuu ku xirnaan doonaa xaaladda bukaanka gaarka ah. Si aad u ogaato wax badan oo ku saabsan cilmi-baarista kansarka booqo Shandong Baofa Machadka Cilmi-baarista KansarkaTijaabooyinka kiliinikada waa daraasado cilmi baaris oo qiimeeya daawaynta cusub ama isku darka daaweynta. Bukaanka qaba NSCLC waxaa laga yaabaa inay tixgeliso ka qaybqaadashada tijaabooyinka bukaan-socodka si loo helo daawaynta heer-goyn. Macluumaadka ku saabsan tijaabooyinka bukaan-socodka waxaa laga heli karaa bogga machadka kansarka qaranka iyo ilo kale oo sumcad leh. Side Effect ManagementAll daawaynta NSCLC waxay keeni kartaa waxyeelo. Waa muhiim inaad kala hadasho dhakhtarkaaga waxyeelada soo raaca oo aad barato sida loo maareeyo. Daryeelka taageerada, sida maareynta xanuunka iyo taageerada nafaqeynta, ayaa gacan ka geysan karta hagaajinta tayada nolosha inta lagu jiro daawaynta. Saadaasha iyo Daryeelka Dabagalka Saadaasha NSCLC waxay ku xidhan tahay heerka kansarka, caafimaadka guud ee bukaanka, iyo sida wanaagsan ee uu kansarku uga jawaabo daawaynta. Ballamaha dabagalka joogtada ah ayaa lama huraan u ah si loola socdo soo noqoshada oo loo maareeyo saameynaha daawaynta ee muddada dheer.Afeef: Maqaalkani waxa uu bixiyaa macluumaad guud oo ku saabsan daawaynta kansarka sambabada unugyada yaryar (NSCLC). waana in aan loo qaadan talo caafimaad. Had iyo jeer la tasho dhakhtarkaaga ama xirfadle daryeel caafimaad oo kale oo u qalma talooyinka shakhsi ahaaneed ee ku saabsan xaaladdaada caafimaad ee gaarka ah.